Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease.
about
Integration of PKPD relationships into benefit-risk analysisThe chronic gastrointestinal consequences associated with campylobacter.Safety considerations when using anti-TNFα therapy to treat Crohn's disease.Inflammatory bowel disease meta-evidence and its challenges: is it time to restructure surgical research?Natalizumab in the treatment of Crohn's disease patients.
P2860
Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk-benefit analysis of adali ...... patients with Crohn's disease.
@en
Risk-benefit analysis of adali ...... patients with Crohn's disease.
@nl
type
label
Risk-benefit analysis of adali ...... patients with Crohn's disease.
@en
Risk-benefit analysis of adali ...... patients with Crohn's disease.
@nl
prefLabel
Risk-benefit analysis of adali ...... patients with Crohn's disease.
@en
Risk-benefit analysis of adali ...... patients with Crohn's disease.
@nl
P2093
P2860
P356
P1476
Risk-benefit analysis of adali ...... patients with Crohn's disease.
@en
P2093
Jingdong Chao
Parvez M Mulani
Scott J Johnson
Si-Tien Wang
P2860
P304
P356
10.1002/IBD.21341
P577
2011-01-01T00:00:00Z